Prolinx, Inc.
ProLynx Inc specializes in innovative drug delivery systems that extend the half-life of therapeutic agents, enabling sustained and predictable drug levels. Their proprietary β-eliminative drug delivery technology uses novel linkers for controlled, long-term release of peptides, proteins, and small molecules, supporting the development of novel therapeutics and collaborations with pharmaceutical companies and academic institutions.
Industries
Nr. of Employees
small (1-50)
Prolinx, Inc.
Products
PLX038 (PEG~SN-38)
A long-acting PEGylated prodrug that slowly releases SN-38 (a topoisomerase I inhibitor) to extend exposure, lower Cmax, accumulate in solid tumors, and be used in combination with DNA damage response inhibitors.
Long-acting PARP inhibitor prodrug (PLX376)
PEG-conjugated long-acting PARP inhibitor designed for single-injection, month-long tumor exposure and combination use with DNA-damaging agents.
Long-acting IL-15 (PLX015)
Microsphere-based long-acting IL-15 designed to reduce Cmax and extend cytokine exposure to expand NK and CD8+ T cells for immuno-oncology applications.
Long-acting C-type natriuretic peptide formulations (PLX138)
Microsphere-based long-acting CNP conjugates intended to convert daily/subcutaneous regimens to biweekly or monthly administration for growth disorders.
Platform for long-acting intravitreal and ocular delivery
Application of PEG-hydrogel and releasable-linker technologies to intravitreal delivery of small molecules and peptides for ocular disorders.
PLX038 (PEG~SN-38)
A long-acting PEGylated prodrug that slowly releases SN-38 (a topoisomerase I inhibitor) to extend exposure, lower Cmax, accumulate in solid tumors, and be used in combination with DNA damage response inhibitors.
Long-acting PARP inhibitor prodrug (PLX376)
PEG-conjugated long-acting PARP inhibitor designed for single-injection, month-long tumor exposure and combination use with DNA-damaging agents.
Long-acting IL-15 (PLX015)
Microsphere-based long-acting IL-15 designed to reduce Cmax and extend cytokine exposure to expand NK and CD8+ T cells for immuno-oncology applications.
Long-acting C-type natriuretic peptide formulations (PLX138)
Microsphere-based long-acting CNP conjugates intended to convert daily/subcutaneous regimens to biweekly or monthly administration for growth disorders.
Platform for long-acting intravitreal and ocular delivery
Application of PEG-hydrogel and releasable-linker technologies to intravitreal delivery of small molecules and peptides for ocular disorders.
Services
Collaborative drug-conjugate design and development
Design and synthesis of releasable drug conjugates and microsphere depots to extend half-life of peptides, proteins, and small molecules for partner programs.
Preclinical development and translational studies
Preclinical PK/PD, biodistribution, imaging, and efficacy studies to support INDs and early clinical trials.
Collaborative drug-conjugate design and development
Design and synthesis of releasable drug conjugates and microsphere depots to extend half-life of peptides, proteins, and small molecules for partner programs.
Preclinical development and translational studies
Preclinical PK/PD, biodistribution, imaging, and efficacy studies to support INDs and early clinical trials.
Expertise Areas
- Half-life extension and controlled-release drug delivery
- Prodrug and PEGylated drug design
- Hydrogel biomaterials and microsphere depot formulations
- Preclinical pharmacokinetics and biodistribution
Key Technologies
- Self-cleaving β-eliminative linkers
- PEGylation and PEG-conjugates
- Tetra-PEG hydrogel microspheres
- Prodrug chemistry for long-acting small molecules